Want to join the conversation?
In 2Q16, $ENDP posted revenues of $288MM in its US Branded Pharmaceuticals segment, down 9% from 2Q15. In US Generic Pharmaceuticals, revenues were $565MM, up 67%, primarily attributable to growth from the addition of sales by Par. International Pharmaceuticals revenues were $67MM, down 17% from 2Q15.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.